SecBot SecBot
SECBOTREPLAY Home › Report › RCUS

RCUS · Arcus Biosciences, Inc

Arcus Biosciences, Inc. · DEFA14A filed Apr 21, 2026 at 16:07 ET

At the news

NEUTRALIMPACT 2/10

DEFA14A filed Apr 21, 2026 at 16:07 ET

Arcus Biosciences, Inc. is holding its 2026 Annual Meeting to vote on director elections, auditor appointment ratification, and executive compensation. This is a routine proxy filing, not a shareholder vote outcome. A recent officer departure filing suggests potential governance issues, but the proxy itself is standard.

  • Filing is a DEFA14A, the definitive proxy statement for the 2026 Annual Meeting.
  • Vote items include the election of four directors, ratification of Ernst & Young as auditors, and advisory approval of executive compensation.
  • A recent 8-K filing (March 23, 2026) reported the departure of an officer, which may indicate internal changes.
  • The filing is routine and does not contain material financial information or significant strategic announcements.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access